An interventional study of Target Temperature Management Treatment in Targeted Temperature Management, Cardiac Arrest and Thrombin Function, sponsored by Tang Ziren. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by Tang Ziren · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.
Among the 37 studies in Heart Arrest with a site in China, this one is one of 4 that started in 2024, is one of 5 with no phase, reaches primary completion later than 5 of the 21 other live ones, and was the 25th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
Central China Fuwai Hospital of Zhengzhou University · Sites in China
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–75
Tang Ziren · Sites in China
Ages 18+
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 299 across the 9 interventional studies, 300 across the 28 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 37 have an industry lead sponsor. The 10 most frequent:
Tang Ziren is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Tang Ziren has 5 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Arrest with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07113769Central China Fuwai Hospital of Zhengzhou UniversityPlasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation | 2026-12-30 |
| NCT06353334Tang ZirenButylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial) | 2026-12-31 |
| NCT06974682Capital Medical UniversityEffect of Target Temperature Management on Intestinal Flora and Its Metabolites in Patients With Cardiac Arrest | 2027-06-01 |
| NCT06992843Xiangya Hospital of Central South UniversityNeuroprotection Bundles For Comatose Survivors Following Cardiac Arrest | 2027-08 |
| NCT06241261The University of Hong KongArresting Early Childhood Caries With a Silver Diamine Fluoride Gel | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Heart Arrest with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be a single-center, prospective, randomized controlled trial with an estimated sample size of 64 patients. Eligible patients will be randomly assigned in a 1:1 ratio to receive TTM for either 24 hours or 72 hours. The primary outcome measure will be the changes in thrombin function indices at various time points during TTM treatment in both groups. The secondary endpoints of the study include additional coagulation function indicators, the incidence of bleeding-related events between the two groups, the amount of blood products used, the incidence of thrombotic events, and the CPC scores at 28 days and 6 months for both groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Target Temperature Management Treatment
Procedure: Target Temperature Management Treatment
Target Temperature Management Treatment
Prothrombin Time (PT)
The primary outcome measure is the statistical differences in prothrombin time (PT) between the two groups of patients at various time points.
Time frame: 4 days
Prothrombin Activity (PA)
The primary outcome measure is the statistical differences in prothrombin activity (PA) between the two groups of patients at various time points.
Time frame: 4 days
Activated Partial Thromboplastin Time (APTT)
The primary outcome measure is the statistical differences in activated partial thromboplastin time (APTT) between the two groups of patients at various time points.
Time frame: 4 days
Thrombin Time (TT)
The primary outcome measure is the statistical differences in thrombin time (TT) between the two groups of patients at various time points.
Time frame: 4 days
The concentration of D-dimer (D-D)
The primary outcome measure is the statistical differences in D-dimer (D-D) between the two groups of patients at various time points.
Time frame: 4 days
International Normalized Ratio (INR)
The primary outcome measure is the statistical differences in international normalized ratio (INR) between the two groups of patients at various time points.
Time frame: 4 days
The concentration of plasmin-α2-plasmin inhibitor complex (PIC)
The primary outcome measure is the statistical differences in plasmin-α2-plasmin inhibitor complex (PIC) between the two groups of patients at various time points.
Time frame: 4 days
The concentration of fibrinogen (FBG)
The primary outcome measure is the statistical differences in fibrinogen (FBG) between the two groups of patients at various time points.
Time frame: 4 days
The concentration of thrombin-antithrombin complex (TAT)
The primary outcome measure is the statistical differences in thrombin-antithrombin complex (TAT) between the two groups of patients at various time points.
Time frame: 4 days
The concentration of thrombomodulin (TM)
The primary outcome measure is the statistical differences in thrombomodulin (TM) between the two groups of patients at various time points.
Time frame: 4 days
The concentration of tissue-type plasminogen activator inhibitor complex (T-PAIC)
The primary outcome measure is the statistical differences in tissue-type plasminogen activator inhibitor complex (T-PAIC) between the two groups of patients at various time points.
Time frame: 4 days
thrombelastogram (TEG)
The primary outcome measure is the statistical differences in thrombelastogram (TEG) between the two groups of patients at various time points.
Time frame: 4 days
Platelet Count (PLT)
The primary outcome measure is the statistical differences in platelet count (PLT) between the two groups of patients at various time points.
Time frame: 4 days
The rate of bleeding-related events
The incidence of bleeding-related events in the two groups of patients, including gastric occult blood, fecal occult blood, intracerebral hemorrhage, or bleeding in other organs.
Time frame: 4 days
The Milliliters of blood products
The usage of blood products, including red blood cells, platelets, and fresh frozen plasma.
Time frame: 4 days
CPC Score
CPC = Cerebral Performance Category Score. The Secondary Outcome of the study is analyzed as the proportion of patients with good neurological outcome in the two groups, (CPC 1-2) at 6 months after CA.
Time frame: 28 days and 6 months
The percentage of serious adverse events during the 4-day treatment period
The primary safety measure is the percentage of serious adverse events during the 4-day treatment period, including any events that cause permanent damage to organs, are life-threatening, or result in death.
Time frame: 4 days
Plan to share: Yes
Supporting information: Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Starting 6 months after publication
Access criteria: The de-identified survey data will be made available for research purposes by contacting the corresponding authors
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.
Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 12 months is below that.
Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tang Ziren